ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.60
-0.34%
US Tech 100
17,650.00
0.05%
S&P 500
5,222.68
0.16%
US Dollar vs CAD
1.36775
0.00%
Bitcoin
60,899.60
0.17%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Xilio Therapeutics Inc (XLO)

  7. Xilio Therapeutics Inc (XLO) News

XLO

Xilio Therapeutics (XLO)

Xilio Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:XLO
DateTimeSourceHeadlineSymbolCompany
05/06/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:XLOXilio Therapeutics Inc
04/01/20243:05PMGlobeNewswire Inc.Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:XLOXilio Therapeutics Inc
03/28/20246:05AMGlobeNewswire Inc.Xilio Therapeutics Announces $11.3 Million Private Placement Equity FinancingNASDAQ:XLOXilio Therapeutics Inc
03/28/20246:00AMBusiness WireGilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 ProgramNASDAQ:XLOXilio Therapeutics Inc
03/28/20246:00AMGlobeNewswire Inc.Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 ProgramNASDAQ:XLOXilio Therapeutics Inc
02/28/20243:01PMGlobeNewswire Inc.Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care ConferenceNASDAQ:XLOXilio Therapeutics Inc
01/31/20243:01PMGlobeNewswire Inc.Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology ConferenceNASDAQ:XLOXilio Therapeutics Inc
01/19/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
01/08/20246:30AMGlobeNewswire Inc.Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology TherapiesNASDAQ:XLOXilio Therapeutics Inc
01/03/20243:38PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
01/03/20243:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
01/03/20243:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
01/03/20243:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
12/07/20236:45AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
12/07/20236:30AMGlobeNewswire Inc.Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy DataNASDAQ:XLOXilio Therapeutics Inc
11/09/20233:17PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XLOXilio Therapeutics Inc
11/09/20233:13PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
11/09/20233:10PMEdgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:XLOXilio Therapeutics Inc
11/09/20233:08PMEdgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:XLOXilio Therapeutics Inc
11/09/20233:05PMEdgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:XLOXilio Therapeutics Inc
11/09/20233:01PMGlobeNewswire Inc.Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial ResultsNASDAQ:XLOXilio Therapeutics Inc
11/03/20233:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
11/03/202311:00AMGlobeNewswire Inc.Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid TumorsNASDAQ:XLOXilio Therapeutics Inc
10/31/20238:15AMGlobeNewswire Inc.Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual MeetingNASDAQ:XLOXilio Therapeutics Inc
09/27/20234:02PMGlobeNewswire Inc.Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:XLOXilio Therapeutics Inc
09/07/20233:26PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
09/07/20233:23PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:XLOXilio Therapeutics Inc
09/05/20237:35AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XLOXilio Therapeutics Inc
09/05/20237:30AMGlobeNewswire Inc.Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development OfficerNASDAQ:XLOXilio Therapeutics Inc
09/05/20236:30AMGlobeNewswire Inc.Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare ConferenceNASDAQ:XLOXilio Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:XLO

Your Recent History

USOTC
SRMX
Saddle Ranch Media (PK)
NASDAQ
RNAZ
TransCode Therapeutics
USOTC
FMCC
Federal Home Loan Mortgage (QB)
NASDAQ
SEV
Sono Group NV
USOTC
FNMA
Fannie Mae (QB)
USOTC
IFUS
Impact Fusion (PK)
USOTC
GVSI
Good Vibrations Shoes (PK)
USOTC
AXXA
Exxe (PK)
USOTC
VPLM
Voip Pal Com (QB)
USOTC
NWBO
Northwest Biotherapeutics (QB)
USOTC
ILST
International Star (PK)
USOTC
AFFU
Affluence (PK)
NASDAQ
COOP
Mr Cooper
NASDAQ
DJT
Trump Media and Technology
COIN
SHIBUSD
SHIBA INU
NASDAQ
AVXL
Anavex Life Sciences
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved